ReviewFrontiers in oncology2026
Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted radionuclide therapy (TRT) delivers ionizing radiation directly to cancer cells through radio molecules that bind tumor-associated targets. Clinically successful examples include somatostatin receptor-directed TRT for neuroendocrine tumors, and prostate specific membrane antigen-targeted TRT for prostate cancer. Despite these advances, therapeutic efficacy remains limited by sublethal tumor doses, heterogeneous intratumoral uptake, and intrinsic radioresistance. A major challenge in improving TRT is the continued reliance on radiobiological concepts derived from external beam radiotherapy (EBRT). In contrast to EBRT, TRT is characterized by prolonged exposure times, low and variable dose rates, heterogeneous energy deposition, and radiation qualities ranging from low-linear energy transfer (LET) β
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.